Prucalopride exerts neuroprotection in human enteric neurons

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 310, Issue 10, 2016, Pages G768-G775

  Bianco, Francesca ^a   Bonora, Elena ^a   Natarajan, Dipa ^b   Vargiolu, Manuela ^a   Thapar, Nikhil ^a   Torresan, Francesco ^c   Giancola, Fiorella ^a   Boschetti, Elisa ^a   Volta, Umberto ^a   Bazzoli, Franco ^a   Mazzoni, Maurizio ^a   Seri, Marco ^a   Clavenzani, Paolo ^a   Stanghellini, Vincenzo ^a   Sternini, Catia ^d   de Giorgio, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 HT4full agonist; Enterokinetic drug; Prucalopride; Serotonin

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; CASPASE 3; CASPASE 9; HYDROGEN PEROXIDE; PRUCALOPRIDE; SULFORHODAMINE B; BENZOFURAN DERIVATIVE; NEUROPROTECTIVE AGENT; SEROTONIN 4 AGONIST;

ADULT; ANIMAL CELL; ARTICLE; CELL SURVIVAL; COLON BIOPSY; CONTROLLED STUDY; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; FLUORESCENCE ANALYSIS; GASTROINTESTINAL DISEASE; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINAL DYSMOTILITY; INTESTINE INNERVATION; NERVE CELL DEGENERATION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SUBMUCOSA; ANIMAL; APOPTOSIS; CYTOLOGY; DRUG EFFECTS; HEK293 CELL LINE; INNERVATION; INTESTINE; MALE; METABOLISM; MIDDLE AGED; MOUSE; NERVE CELL; TUMOR CELL LINE;

ADULT; ANIMALS; APOPTOSIS; BENZOFURANS; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HUMANS; INTESTINES; MALE; MICE; MIDDLE AGED; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; SEROTONIN 5-HT4 RECEPTOR AGONISTS;

EID: 84976267480     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00036.2016     Document Type: Article

References (27)

1. Anderson G, Maes M. Neurodegeneration in Parkinson’s disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins. Mol Neurobiol 49: 771-783, 2014.
2. Bondurand N, Natarajan D, Thapar N, Atkins C, Pachnis V. Neuron and glia generating progenitors of the mammalian enteric nervous system isolated from foetal and postnatal gut cultures. Development 130: 6387-6400, 2003.
3. Clement MV, Ponton A, Pervaiz S. Apoptosis induced by hydrogen peroxide is mediated by decreased superoxide anion concentration and reduction of intracellular milieu. FEBS Lett 440: 13-18, 1998.
4. Coupar IM, Desmond PV, Irving HR. Human 5-HT4 and 5-HT7 receptor splice variants: are they important? Curr Neuropharmacol 5: 224-231, 2007.
5. Danial N, Korsmeyer SJ. Cell death: critical control points. Cell 116: 205-219, 2004.
6. De Giorgio R, Barbara G, Furness JB, Tonini M. Novel therapeutic targets for enteric nervous system disorders. Trends Pharmacol Sci 28: 473-481, 2007.
7. De Giorgio R, Bovara M, Barbara G, Canossa M, Sarnelli G, De Ponti F, Stanghellini V, Tonini M, Cappello S, Pagnotta E, Nobile-Orazio E, Corinaldesi R. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology 125: 70-79, 2003.
8. Emmanuel A, Cools M, Vandeplassche L, Kerstens R. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. Am J Gastroenterol 109: 887-894, 2014.
9. Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol 9: 286-294, 2012.
10. Gale JD, Grossman CJ, Whitehead JW, Oxford AW, Bunce KT, Humphrey PP. GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor. Br J Pharmacol 111: 332-338, 1994.
11. Gershon MD, Liu MT. Serotonin and neuroprotection in functional bowel disorders. Neurogastroenterol Motil 19, Suppl 2: 19-24, 2007.
12. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397-414, 2007.
13. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 20: 14-21, 2013.
14. Gershon MD. 5-HT4-mediated neuroprotection: a new therapeutic modality on the way? Am J Physiol Gastrointest Liver Physiol (March 24, 2016). doi:10.1152/ajpgi.00120.2016.
15. Irwin RW, Brinton RD. Allopregnanolone as regenerative therapeutic for Alzheimer’s disease: translational development and clinical promise. Prog Neurobiol 113: 40-55, 2014.
16. Knowles CH, Lindberg G, Panza E, De Giorgio R. New perspectives in the diagnosis and management of enteric neuropathies. Nat Rev Gastroenterol Hepatol 10: 206-218, 2013.
17. Lebouvier T, Coron E, Chaumette T, Paillusson S, Bruley des Varannes S, Neunlist M, Derkinderen P. Routine colonic biopsies as a new tool to study the enteric nervous system in living patients. Neurogastroenterol Motil 22: e11-e14, 2010.
18. Liu MT, Kuan YH, Wang J, Hen R, Gershon MD. 5-HT4 receptormediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J Neurosci 29: 9683-9699, 2009.
19. Matsuyoshi H, Kuniyasu H, Okumura M, Misawa H, Katsui R, Zhang GX, Obata K, Takaki M. A 5-HT4-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult. Neurogastroenterol Motil 22: 806-813, e226, 2010.
20. Mawe GM, Hoffman JM. Serotonin signaling in the gut — functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 10: 473-486, 2013.
21. Park SY, Kim do Y, Kang JK, Park G, Choi YW. Involvement of activation of the Nrf2/ARE pathway in protection against 6-OHDAinduced SH-SY5Y cell death by α-iso-cubebenol. Neurotoxicology 44: 160-168, 2014.
22. Poole DP, Xu B, Koh SL, Hunne B, Coupar IM, Irving HR, Shinjo K, Furness JB. Identification of neurons that express 5-hydroxytryptamine4 receptors in intestine. Cell Tissue Res 325: 413-422, 2006.
23. Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, Müller-Lissner S, Quigley EM, Schuurkes J, De Maeyer JH, Stanghellini V. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 35: 745-767, 2012.
24. Takaki M, Goto K, Kawahara I. The 5-hydroxytryptamine 4 receptor agonist-induced actions and enteric neurogenesis in the gut. J Neurogastroenterol Motil 20: 17-30, 2014.
25. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112-1116, 2006.
26. Waeber C, Sebben M, Nieoullon A, Bockaert J, Dumuis A. Regional distribution and ontogeny of 5-HT4 binding sites in rodent brain. Neuropharmacology 33: 527-541, 1994.
27. Wong BS, Manabe N, Camilleri M. Role of prucalopride, a serotonin (5-HT-4) receptor agonist, for the treatment of chronic constipation. Clin Exp Gastroenterol 3: 49-56, 2010.